The availability of new and repurposed drugs for the treatment of drug-resistant tuberculosis (DR-TB) provides hope in a field in which treatment options are severely limited and treatment success rates rarely exceed 50%. Despite the ongoing search for shorter, more tolerable, and more efficacious treatment regimens, DR-TB remains a death sentence for a considerable proportion of people affected. Additionally, these patients must bear debilitating side-effects of centuries-old medication, along with social isolation, stigma, loss of income, and psychological distress.

中文翻译：

---

抗药性肺结核的姑息治疗：新药不足时

在治疗选择受到严重限制且治疗成功率很少超过50％的领域，可获得用于治疗抗药性肺结核（DR-TB）的新药和重新用途的药物提供了希望。尽管人们一直在寻找更短，更宽容和更有效的治疗方案，但耐药结核仍然是相当多受影响人群的死刑。此外，这些患者必须承担数百年之久的药物所带来的令人衰弱的副作用，以及社会隔离，污名，收入损失和心理困扰。